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T cells in peripheral blood and bone marrow associated with 
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The transcription factor Wilms tumor protein 1 (WT1) is
an interesting antigen for use in vaccination and T cell
therapy in myeloid leukemias. WT1 is strongly expressed
in the majority of myeloid leukemic blasts and is a key
molecule for blast proliferation. A phase I/II study has
been initiated in our institution in patients with acute
myeloid leukemia to analyze the immunogenicity and
toxicity of WT1 126–134 peptide vaccination ín combina-
tion with the adjuvants GM-CSF and keyhole limpet
hemocyanin. We report here on the first 4 patients who
have completed vaccination and have received a total of
15, 12, 5, and 5 vaccination cycles, respectively. While,
following chemotherapy, patients 1 and 2 both had 5–
10% blasts in bone marrow when vaccination was initi-
ated, patient 3 and 4 had 90% and 70% blasts, respec-
tively. Induction of high frequency T cell responses was
detected in 3 of 4 patients with up to 0.92%, 0.43%, and
0.42% in peripheral blood and up to 0.8% in bone mar-
row by tetramer analysis. Detailed phenotypical analysis
in patient 1 showed that WT1-specific peripheral blood T
cells were almost exclusively CD45RA+CCR7-
granzymeB+, and directly produced IFNγ in response to
WT1 peptide, resembling cytotoxic effector T cells, while
in the bone marrow both WT1-specific effector and
CD45RA-CCR7- effector memory T cells were found.
Patient 3 and 4 had progressive disease after 5 vaccina-
tions. Patient 1 who had progressed during the first 4
weeks of vaccination with an increase of blasts to 30% in
bone marrow was induced into complete remission after
6 vaccinations, which lasted for 12 months. Patient 2 is in
continuous remission for currently 20 months. WT1 tran-
scripts in bone marrow and peripheral blood were quan-
titated by PCR to monitor residual disease. In accordance
with the clinical course in patients 1 and 2 we observed an
approximately 100-fold, and 50-fold reduction, respec-
tively, of WT1 transcripts following vaccination. No side
effects as those typically seen with GM-CSF were noted.
Taken together, these findings underline the efficacy of
the vaccine, inducing high frequency WT1-specific effector
and memory T cells in peripheral blood and bone marrow
associated with complete remission of leukemia in the
absence of hematological or renal toxicity.
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